Pharmacia Corporation

Mark A Nagy

John Jeffrey Talley

John Nicholas Freskos

Ish K Khanna

Daniel Paul Becker

Deborah A Mischke

Robert M Heintz

David Louis Brown

Joseph J McDonald

Thomas E Barta

Yvette M Fobian

Clara I Villamil

Lijuan Jane Wang

Margaret Lanahan Grapperhaus

Mark A Massa

Monica B Norton

William F Vernier

Joseph Gerace Rico

Susan Landis Hockerman

Alan Frank Gasiecki

Terri L Boehm

Louis J Bedell

Jeffery N Carroll

Brent V Mischke

Darren J Kassab

Nathan W Stehle

Stephen A Kolodziej

Patrick B Mullins

Michelle A Schmidt

Yiyuan Chen

Thomas A Wynn

This invention is directed generally to proteinase (also known as 'protease') inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as 'matrix metalloprotease' or &#x201c;MMP&#x201d;) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A, A, Y, E, E, E, and Rare as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.

Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors

Growing community of inventors

Chesterfield, MO, United States of America

Mark A Nagy